[Immunoglobulin therapy of primary humoral immunologic deficiencies]

There is a strong body of evidence documenting that immunoglobulin therapy reduces the incidence and severity of infections in patients with primary humoral immunodeficiencies, whatever patient's age. Health-related quality of life is significantly improved in particular by self-infusions of subcutaneous immunoglobulins. Residual levels of total IgG over 6-800 mg/dL may help prevent progression of lung damage. Levels of IgG, clinical manifestations, pulmonary function tests and high resolution computed tomography routine surveillance is recommended.